Calegaro J U M, Machado J, Furtado R G, de Almeida J S C, de Vasconcelos A V P, de Barboza M F, de Paula A P
Grupo Núcleos of Nuclear Medicine, Hospital de Base, Brasilia, DF, Brazil.
Haemophilia. 2014 May;20(3):421-5. doi: 10.1111/hae.12319. Epub 2013 Dec 16.
The penetration of beta energy of 153-samarium ((153) Sm) (0.8 MeV) is not only appropriate for synovectomy of median articulations but is possible to improve the radiobiological effect using increased activities. The aim of this study was to assess the effectiveness of 185 MBq and 740 MBq of 153-samarium hydroxyapatite ((153) Sm-HA) in knees of haemophilic patients. Thirty-one patients--36 knees, 30 males, were divided into two groups without coinjection of corticosteroid: A - 14 patients (17 knees) treated with intra-articular dose of 185 MBq of (153) Sm-HA, average age 23 years; B--17 patients (19 knees) with 740 MBq of (153) Sm-HA, average age 21.3 years. The evaluation before and after 1 year of synovectomy used the following criteria: reduction in the number of haemarthroses and use of the coagulation factor and improvement in articular motility. Adverse-effects occurrence was considered too. Early and late scintigraphic studies were performed after synoviorthesis and no joint immobilization was recommended. The reduction in haemarthrosis and use of coagulation factor were: group 1--31.3% and 25%; group 2--81.5% and 79% with P < 0.001 respectively; no significant improvement in knees motility was noted for both groups. Four cases of mild reactional synovitis were observed in each group. The scintigraphic control showed homogenous distribution of the radiopharmaceuticals with no articular escape; the material was considered safe by its permanence in the articulation. We have significant improvement in the synovectomy of haemophilic knees with 740 MBq of (153) Sm-HA; the less penetration of its beta radiation was compensated by the increased biological effect with the higher used activity.
153-钐(¹⁵³Sm)的β射线能量(0.8兆电子伏特)不仅适用于中关节滑膜切除术,而且有可能通过增加活度来提高放射生物学效应。本研究的目的是评估185兆贝可和740兆贝可的153-钐羟基磷灰石(¹⁵³Sm-HA)在血友病患者膝关节中的有效性。31例患者(36个膝关节,30例男性)被分为两组,未联合注射皮质类固醇:A组14例患者(17个膝关节),关节腔内注射185兆贝可的¹⁵³Sm-HA治疗,平均年龄23岁;B组17例患者(19个膝关节),注射740兆贝可的¹⁵³Sm-HA,平均年龄21.3岁。滑膜切除术前和术后1年的评估使用以下标准:关节积血次数和凝血因子使用量的减少以及关节活动度的改善。还考虑了不良反应的发生情况。滑膜切除术后进行了早期和晚期闪烁显像研究,不建议关节固定。关节积血和凝血因子使用量的减少情况如下:第1组分别为31.3%和25%;第2组分别为81.5%和79%,P均<0.001;两组膝关节活动度均未出现显著改善。每组均观察到4例轻度反应性滑膜炎病例。闪烁显像对照显示放射性药物分布均匀,无关节渗漏;由于其在关节内的持久性,该物质被认为是安全的。使用740兆贝可的¹⁵³Sm-HA对血友病膝关节进行滑膜切除术有显著改善;其β射线较低的穿透性通过较高活度增加的生物学效应得到了补偿。